Review



fty720p  (Santa Cruz Biotechnology)


Bioz Verified Symbol Santa Cruz Biotechnology is a verified supplier  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 86
      Buy from Supplier

    Structured Review

    Santa Cruz Biotechnology fty720p
    Figure 2. S1P and <t>FTY720P</t> induce lipid accumulation in HepG2 cells. Lipid accumulation in the presence of (a) Sphk1 inhibitor PF543; (b) blockers of all S1PRs. Values are means ± SEM. N = 4. Bars not sharing a common letter are considered significantly different from each other at P < 0.05; c) various concentrations of the S1P analog FTY720P. Values are means ± SEM; N = 3. *Significantly different from the control at P < 0.05.
    Fty720p, supplied by Santa Cruz Biotechnology, used in various techniques. Bioz Stars score: 86/100, based on 7 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/fty720p/pm37953311-62-0-47?v=Santa+Cruz+Biotechnology
    Average 86 stars, based on 7 article reviews
    fty720p - by Bioz Stars, 2026-08
    86/100 stars

    Images

    1) Product Images from "Effect of FTY720P on lipid accumulation in HEPG2 cells."

    Article Title: Effect of FTY720P on lipid accumulation in HEPG2 cells.

    Journal: Scientific reports

    doi: 10.1038/s41598-023-46011-4

    Figure 2. S1P and FTY720P induce lipid accumulation in HepG2 cells. Lipid accumulation in the presence of (a) Sphk1 inhibitor PF543; (b) blockers of all S1PRs. Values are means ± SEM. N = 4. Bars not sharing a common letter are considered significantly different from each other at P < 0.05; c) various concentrations of the S1P analog FTY720P. Values are means ± SEM; N = 3. *Significantly different from the control at P < 0.05.
    Figure Legend Snippet: Figure 2. S1P and FTY720P induce lipid accumulation in HepG2 cells. Lipid accumulation in the presence of (a) Sphk1 inhibitor PF543; (b) blockers of all S1PRs. Values are means ± SEM. N = 4. Bars not sharing a common letter are considered significantly different from each other at P < 0.05; c) various concentrations of the S1P analog FTY720P. Values are means ± SEM; N = 3. *Significantly different from the control at P < 0.05.

    Techniques Used: Control

    Figure 3. Effect of FTY720P on lipid accumulation in the presence of (a) S1PR1 blocker W146. (b) S1PR2 blocker JTE 013. (c) S1PR4 blocker CYM50358. Values are means ± SEM; N = 5. Bars not sharing a common letter are considered significantly different from each other at P < 0.05.
    Figure Legend Snippet: Figure 3. Effect of FTY720P on lipid accumulation in the presence of (a) S1PR1 blocker W146. (b) S1PR2 blocker JTE 013. (c) S1PR4 blocker CYM50358. Values are means ± SEM; N = 5. Bars not sharing a common letter are considered significantly different from each other at P < 0.05.

    Techniques Used:

    Figure 4. S1PR3 and Gq mediate the FTY720P effect on lipid accumulation. (a) Effect of FTY720P on lipid accumulation in the presence of S1PR3 blocker CAY10444. (b) Effect of FTY720P on lipid accumulation in the presence of the Gq inhibitor YM254890. (c) Protein expression of S1PR3. The blot is representative of an experiment repeated 3 times. Values were normalized to GAPDH and reported as arbitrary densitometry units. All values are means ± SEM; N = 3. Bars not sharing a common letter are considered significantly different from each other at P < 0.05.
    Figure Legend Snippet: Figure 4. S1PR3 and Gq mediate the FTY720P effect on lipid accumulation. (a) Effect of FTY720P on lipid accumulation in the presence of S1PR3 blocker CAY10444. (b) Effect of FTY720P on lipid accumulation in the presence of the Gq inhibitor YM254890. (c) Protein expression of S1PR3. The blot is representative of an experiment repeated 3 times. Values were normalized to GAPDH and reported as arbitrary densitometry units. All values are means ± SEM; N = 3. Bars not sharing a common letter are considered significantly different from each other at P < 0.05.

    Techniques Used: Expressing

    Figure 5. Effect of FTY720P on lipid accumulation in the presence of (a) the PI3K inhibitor wortmannin. (b) the mTOR inhibitor rapamycin. All values are means ± SEM; N = 4. Bars not sharing a common letter are considered significantly different from each other at P < 0.05.
    Figure Legend Snippet: Figure 5. Effect of FTY720P on lipid accumulation in the presence of (a) the PI3K inhibitor wortmannin. (b) the mTOR inhibitor rapamycin. All values are means ± SEM; N = 4. Bars not sharing a common letter are considered significantly different from each other at P < 0.05.

    Techniques Used:

    Figure 6. Effect of FTY720P on lipid accumulation in the presence of (a) the SREBP inhibitor fatostatin. (b) The PPARγ inhibitor GW9662. Values are means ± SEM; N = 5. Bars not sharing a common letter are considered significantly different from each other at P < 0.05.
    Figure Legend Snippet: Figure 6. Effect of FTY720P on lipid accumulation in the presence of (a) the SREBP inhibitor fatostatin. (b) The PPARγ inhibitor GW9662. Values are means ± SEM; N = 5. Bars not sharing a common letter are considered significantly different from each other at P < 0.05.

    Techniques Used:

    Figure 13. The signaling pathway activated by FTY720P.
    Figure Legend Snippet: Figure 13. The signaling pathway activated by FTY720P.

    Techniques Used:



    Similar Products

    fty720 phosphate fty720p  (Cayman Chemical)
    90
    Cayman Chemical fty720 phosphate fty720p
    Fty720 Phosphate Fty720p, supplied by Cayman Chemical, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/fty720p/pm40307450-673-0-3?v=Cayman+Chemical
    Average 90 stars, based on 1 article reviews
    fty720 phosphate fty720p - by Bioz Stars, 2026-08
    90/100 stars
    		  Buy from Supplier
    fty720p  (MedChemExpress)
    98
    MedChemExpress fty720p
    Fty720p, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 98/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/fty720p/pm40012038-82-3-8?v=MedChemExpress
    Average 98 stars, based on 1 article reviews
    fty720p - by Bioz Stars, 2026-08
    98/100 stars
    		  Buy from Supplier
    fty720p cayman 10008639  (Cayman Chemical)
    90
    Cayman Chemical fty720p cayman 10008639
    Fty720p Cayman 10008639, supplied by Cayman Chemical, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/fty720p/10__1016_slash_j__jcyt__2024__11__002-51-20-21?v=Cayman+Chemical
    Average 90 stars, based on 1 article reviews
    fty720p cayman 10008639 - by Bioz Stars, 2026-08
    90/100 stars
    		  Buy from Supplier
    fty720p  (Novartis)
    90
    Novartis fty720p
    (A‒C) Specific binding curves between CD320 vs. TCN2 and B12 (A), FTY720 and <t>FTY720P</t> (B), and sphingosine (Sph) and S1P (C). (D‒F) Specific binding curves between TCN2 vs. B12 (D), FTY720 and FTY720P (E), and Sph and S1P (F). Compensated interferometric reader (CIR) signals are plotted against concentrations of binding partners and fitted by non-linear regression using the Michaelis-Menten equation (mean ± SEM, n = 6–7). (G) Computational modeling of FTY720 binding site on TCN2 (PDB: 4ZRP). Cartoon representation of TCN2 (light gray) and LDLR domains of CD320 (dark gray) (left) and electrostatic surface of these complex (right). (H) Magnified view of a potential FTY720 binding site in TCN2. Interactions are represented by dashed lines with distances between atoms (Å). (I) CIR binding signals of WT-TCN2 and mutant TCN2 (Mut-TCN2) to 100 nM FTY720 (mean ± SEM, n = 16 and 8 for WT-TCN2 and Mut-TCN2, respectively, pooled from at least 2 independent experiments; *p < 0.05 by one-way ANOVA with Dunn’s multiple comparisons test; N.S., non-significant). (J) A representative flow cytometry (FCM) histogram of CD320 expression on HASTR/ci35 cells stimulated with or without FTY720 (1 μM) in the presence or absence of FBS (left). Normalized CD320 expression levels (mean ± SEM, n = 6–7, pooled from 2 independent experiments; *p < 0.05 by Kruskal-Wallis test with Dunn’s multiple comparisons test; N.S., non-significant).
    Fty720p, supplied by Novartis, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/fty720p/pmc11066976-573-24-25?v=Novartis
    Average 90 stars, based on 1 article reviews
    fty720p - by Bioz Stars, 2026-08
    90/100 stars
    		  Buy from Supplier
    fty720p  (Santa Cruz Biotechnology)
    86
    Santa Cruz Biotechnology fty720p
    Figure 2. S1P and <t>FTY720P</t> induce lipid accumulation in HepG2 cells. Lipid accumulation in the presence of (a) Sphk1 inhibitor PF543; (b) blockers of all S1PRs. Values are means ± SEM. N = 4. Bars not sharing a common letter are considered significantly different from each other at P < 0.05; c) various concentrations of the S1P analog FTY720P. Values are means ± SEM; N = 3. *Significantly different from the control at P < 0.05.
    Fty720p, supplied by Santa Cruz Biotechnology, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/fty720p/pm37953311-62-0-47?v=Santa+Cruz+Biotechnology
    Average 86 stars, based on 1 article reviews
    fty720p - by Bioz Stars, 2026-08
    86/100 stars
    		  Buy from Supplier
    fty720p  (Cayman Chemical)
    90
    Cayman Chemical fty720p
    Figure 2. S1P and <t>FTY720P</t> induce lipid accumulation in HepG2 cells. Lipid accumulation in the presence of (a) Sphk1 inhibitor PF543; (b) blockers of all S1PRs. Values are means ± SEM. N = 4. Bars not sharing a common letter are considered significantly different from each other at P < 0.05; c) various concentrations of the S1P analog FTY720P. Values are means ± SEM; N = 3. *Significantly different from the control at P < 0.05.
    Fty720p, supplied by Cayman Chemical, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/fty720p/pm37474025-149-20-21?v=Cayman+Chemical
    Average 90 stars, based on 1 article reviews
    fty720p - by Bioz Stars, 2026-08
    90/100 stars
    		  Buy from Supplier

    Image Search Results


    (A‒C) Specific binding curves between CD320 vs. TCN2 and B12 (A), FTY720 and FTY720P (B), and sphingosine (Sph) and S1P (C). (D‒F) Specific binding curves between TCN2 vs. B12 (D), FTY720 and FTY720P (E), and Sph and S1P (F). Compensated interferometric reader (CIR) signals are plotted against concentrations of binding partners and fitted by non-linear regression using the Michaelis-Menten equation (mean ± SEM, n = 6–7). (G) Computational modeling of FTY720 binding site on TCN2 (PDB: 4ZRP). Cartoon representation of TCN2 (light gray) and LDLR domains of CD320 (dark gray) (left) and electrostatic surface of these complex (right). (H) Magnified view of a potential FTY720 binding site in TCN2. Interactions are represented by dashed lines with distances between atoms (Å). (I) CIR binding signals of WT-TCN2 and mutant TCN2 (Mut-TCN2) to 100 nM FTY720 (mean ± SEM, n = 16 and 8 for WT-TCN2 and Mut-TCN2, respectively, pooled from at least 2 independent experiments; *p < 0.05 by one-way ANOVA with Dunn’s multiple comparisons test; N.S., non-significant). (J) A representative flow cytometry (FCM) histogram of CD320 expression on HASTR/ci35 cells stimulated with or without FTY720 (1 μM) in the presence or absence of FBS (left). Normalized CD320 expression levels (mean ± SEM, n = 6–7, pooled from 2 independent experiments; *p < 0.05 by Kruskal-Wallis test with Dunn’s multiple comparisons test; N.S., non-significant).

    Journal: Cell reports

    Article Title: FTY720 requires vitamin B 12 -TCN2-CD320 signaling in astrocytes to reduce disease in an animal model of multiple sclerosis

    doi: 10.1016/j.celrep.2023.113545

    Figure Lengend Snippet: (A‒C) Specific binding curves between CD320 vs. TCN2 and B12 (A), FTY720 and FTY720P (B), and sphingosine (Sph) and S1P (C). (D‒F) Specific binding curves between TCN2 vs. B12 (D), FTY720 and FTY720P (E), and Sph and S1P (F). Compensated interferometric reader (CIR) signals are plotted against concentrations of binding partners and fitted by non-linear regression using the Michaelis-Menten equation (mean ± SEM, n = 6–7). (G) Computational modeling of FTY720 binding site on TCN2 (PDB: 4ZRP). Cartoon representation of TCN2 (light gray) and LDLR domains of CD320 (dark gray) (left) and electrostatic surface of these complex (right). (H) Magnified view of a potential FTY720 binding site in TCN2. Interactions are represented by dashed lines with distances between atoms (Å). (I) CIR binding signals of WT-TCN2 and mutant TCN2 (Mut-TCN2) to 100 nM FTY720 (mean ± SEM, n = 16 and 8 for WT-TCN2 and Mut-TCN2, respectively, pooled from at least 2 independent experiments; *p < 0.05 by one-way ANOVA with Dunn’s multiple comparisons test; N.S., non-significant). (J) A representative flow cytometry (FCM) histogram of CD320 expression on HASTR/ci35 cells stimulated with or without FTY720 (1 μM) in the presence or absence of FBS (left). Normalized CD320 expression levels (mean ± SEM, n = 6–7, pooled from 2 independent experiments; *p < 0.05 by Kruskal-Wallis test with Dunn’s multiple comparisons test; N.S., non-significant).

    Article Snippet: 52 , 53 Recombinant human CD320 (R&D systems, cat # 1557-CD-050) and human TCN2 (R&D systems, cat # 7895-TC-050) were mixed with FTY720 (Novartis), FTY720P (Novartis), sphingosine (Avanti Polar Lipids, cat # 860490P), and S1P (Avanti Polar Lipids, cat # 860492P) and applied to the CIR.

    Techniques: Binding Assay, Mutagenesis, Flow Cytometry, Expressing

    Pink arrows indicate newly identified pathways that contribute to the direct CNS effects of FTY720 beyond functional antagonism of astrocyte S1P1. ① S1P1 inhibition in peripheral lymphocytes is the originally proposed CNS MOA. ② FTY720 is complexed with B12-TCN2. ③ This FTY720-TCN2-B12 complex is taken up by astrocytes via CD320, followed by dissociation of the complex. ④ B12 is essential for astrocyte IFN-I sensitivity and microglial IFN-β production. ⑤ Astrocyte SK1/2 phosphorylates FTY720 to form FTY720P.35 ⑥ The resulting FTY720P may be transported via SPNS256 and functionally antagonizes S1P1 in an autocrine/paracrine manner. ⑦ FTY720P functionally antagonizes astrocyte S1P1 and downregulates cell surface expression of S1P1. Ⓑ Astrocytic S1P1 inhibition increases CD320 expression, enabling increased engagement of and astrocyte internalization of the B12-TCN2-FTY720 complex. SK1/2, sphingosine kinase 1/2; SPNS2, SPNS lysolipid transporter 2; TCN2, transcobalamin; IFNAR, interferon α/β receptor.

    Journal: Cell reports

    Article Title: FTY720 requires vitamin B 12 -TCN2-CD320 signaling in astrocytes to reduce disease in an animal model of multiple sclerosis

    doi: 10.1016/j.celrep.2023.113545

    Figure Lengend Snippet: Pink arrows indicate newly identified pathways that contribute to the direct CNS effects of FTY720 beyond functional antagonism of astrocyte S1P1. ① S1P1 inhibition in peripheral lymphocytes is the originally proposed CNS MOA. ② FTY720 is complexed with B12-TCN2. ③ This FTY720-TCN2-B12 complex is taken up by astrocytes via CD320, followed by dissociation of the complex. ④ B12 is essential for astrocyte IFN-I sensitivity and microglial IFN-β production. ⑤ Astrocyte SK1/2 phosphorylates FTY720 to form FTY720P.35 ⑥ The resulting FTY720P may be transported via SPNS256 and functionally antagonizes S1P1 in an autocrine/paracrine manner. ⑦ FTY720P functionally antagonizes astrocyte S1P1 and downregulates cell surface expression of S1P1. Ⓑ Astrocytic S1P1 inhibition increases CD320 expression, enabling increased engagement of and astrocyte internalization of the B12-TCN2-FTY720 complex. SK1/2, sphingosine kinase 1/2; SPNS2, SPNS lysolipid transporter 2; TCN2, transcobalamin; IFNAR, interferon α/β receptor.

    Article Snippet: 52 , 53 Recombinant human CD320 (R&D systems, cat # 1557-CD-050) and human TCN2 (R&D systems, cat # 7895-TC-050) were mixed with FTY720 (Novartis), FTY720P (Novartis), sphingosine (Avanti Polar Lipids, cat # 860490P), and S1P (Avanti Polar Lipids, cat # 860492P) and applied to the CIR.

    Techniques: Functional Assay, Inhibition, Expressing

    Figure 2. S1P and FTY720P induce lipid accumulation in HepG2 cells. Lipid accumulation in the presence of (a) Sphk1 inhibitor PF543; (b) blockers of all S1PRs. Values are means ± SEM. N = 4. Bars not sharing a common letter are considered significantly different from each other at P < 0.05; c) various concentrations of the S1P analog FTY720P. Values are means ± SEM; N = 3. *Significantly different from the control at P < 0.05.

    Journal: Scientific reports

    Article Title: Effect of FTY720P on lipid accumulation in HEPG2 cells.

    doi: 10.1038/s41598-023-46011-4

    Figure Lengend Snippet: Figure 2. S1P and FTY720P induce lipid accumulation in HepG2 cells. Lipid accumulation in the presence of (a) Sphk1 inhibitor PF543; (b) blockers of all S1PRs. Values are means ± SEM. N = 4. Bars not sharing a common letter are considered significantly different from each other at P < 0.05; c) various concentrations of the S1P analog FTY720P. Values are means ± SEM; N = 3. *Significantly different from the control at P < 0.05.

    Article Snippet: FTY720P (Cat # sc-205332A), rosiglitazone (Cat # sc-202795), anti-SREBP1 (Cat# sc-365513, Lot#B1821), anti-p-mTOR (Cat# sc-293132, Lot#K2717), anti-mTOR (Cat# sc-8319, Lot#K2415), anti-GAPDH (Cat# sc-47724, Lot# H0917) mouse primary antibodies as well as anti-mouse horse radish peroxidase (HRP) conjugated secondary antibodies (Cat# sc-2005, Lot# C2011) were purchased all from Santa Cruz Biotechnology, CA, USA.

    Techniques: Control

    Figure 3. Effect of FTY720P on lipid accumulation in the presence of (a) S1PR1 blocker W146. (b) S1PR2 blocker JTE 013. (c) S1PR4 blocker CYM50358. Values are means ± SEM; N = 5. Bars not sharing a common letter are considered significantly different from each other at P < 0.05.

    Journal: Scientific reports

    Article Title: Effect of FTY720P on lipid accumulation in HEPG2 cells.

    doi: 10.1038/s41598-023-46011-4

    Figure Lengend Snippet: Figure 3. Effect of FTY720P on lipid accumulation in the presence of (a) S1PR1 blocker W146. (b) S1PR2 blocker JTE 013. (c) S1PR4 blocker CYM50358. Values are means ± SEM; N = 5. Bars not sharing a common letter are considered significantly different from each other at P < 0.05.

    Article Snippet: FTY720P (Cat # sc-205332A), rosiglitazone (Cat # sc-202795), anti-SREBP1 (Cat# sc-365513, Lot#B1821), anti-p-mTOR (Cat# sc-293132, Lot#K2717), anti-mTOR (Cat# sc-8319, Lot#K2415), anti-GAPDH (Cat# sc-47724, Lot# H0917) mouse primary antibodies as well as anti-mouse horse radish peroxidase (HRP) conjugated secondary antibodies (Cat# sc-2005, Lot# C2011) were purchased all from Santa Cruz Biotechnology, CA, USA.

    Techniques:

    Figure 4. S1PR3 and Gq mediate the FTY720P effect on lipid accumulation. (a) Effect of FTY720P on lipid accumulation in the presence of S1PR3 blocker CAY10444. (b) Effect of FTY720P on lipid accumulation in the presence of the Gq inhibitor YM254890. (c) Protein expression of S1PR3. The blot is representative of an experiment repeated 3 times. Values were normalized to GAPDH and reported as arbitrary densitometry units. All values are means ± SEM; N = 3. Bars not sharing a common letter are considered significantly different from each other at P < 0.05.

    Journal: Scientific reports

    Article Title: Effect of FTY720P on lipid accumulation in HEPG2 cells.

    doi: 10.1038/s41598-023-46011-4

    Figure Lengend Snippet: Figure 4. S1PR3 and Gq mediate the FTY720P effect on lipid accumulation. (a) Effect of FTY720P on lipid accumulation in the presence of S1PR3 blocker CAY10444. (b) Effect of FTY720P on lipid accumulation in the presence of the Gq inhibitor YM254890. (c) Protein expression of S1PR3. The blot is representative of an experiment repeated 3 times. Values were normalized to GAPDH and reported as arbitrary densitometry units. All values are means ± SEM; N = 3. Bars not sharing a common letter are considered significantly different from each other at P < 0.05.

    Article Snippet: FTY720P (Cat # sc-205332A), rosiglitazone (Cat # sc-202795), anti-SREBP1 (Cat# sc-365513, Lot#B1821), anti-p-mTOR (Cat# sc-293132, Lot#K2717), anti-mTOR (Cat# sc-8319, Lot#K2415), anti-GAPDH (Cat# sc-47724, Lot# H0917) mouse primary antibodies as well as anti-mouse horse radish peroxidase (HRP) conjugated secondary antibodies (Cat# sc-2005, Lot# C2011) were purchased all from Santa Cruz Biotechnology, CA, USA.

    Techniques: Expressing

    Figure 5. Effect of FTY720P on lipid accumulation in the presence of (a) the PI3K inhibitor wortmannin. (b) the mTOR inhibitor rapamycin. All values are means ± SEM; N = 4. Bars not sharing a common letter are considered significantly different from each other at P < 0.05.

    Journal: Scientific reports

    Article Title: Effect of FTY720P on lipid accumulation in HEPG2 cells.

    doi: 10.1038/s41598-023-46011-4

    Figure Lengend Snippet: Figure 5. Effect of FTY720P on lipid accumulation in the presence of (a) the PI3K inhibitor wortmannin. (b) the mTOR inhibitor rapamycin. All values are means ± SEM; N = 4. Bars not sharing a common letter are considered significantly different from each other at P < 0.05.

    Article Snippet: FTY720P (Cat # sc-205332A), rosiglitazone (Cat # sc-202795), anti-SREBP1 (Cat# sc-365513, Lot#B1821), anti-p-mTOR (Cat# sc-293132, Lot#K2717), anti-mTOR (Cat# sc-8319, Lot#K2415), anti-GAPDH (Cat# sc-47724, Lot# H0917) mouse primary antibodies as well as anti-mouse horse radish peroxidase (HRP) conjugated secondary antibodies (Cat# sc-2005, Lot# C2011) were purchased all from Santa Cruz Biotechnology, CA, USA.

    Techniques:

    Figure 6. Effect of FTY720P on lipid accumulation in the presence of (a) the SREBP inhibitor fatostatin. (b) The PPARγ inhibitor GW9662. Values are means ± SEM; N = 5. Bars not sharing a common letter are considered significantly different from each other at P < 0.05.

    Journal: Scientific reports

    Article Title: Effect of FTY720P on lipid accumulation in HEPG2 cells.

    doi: 10.1038/s41598-023-46011-4

    Figure Lengend Snippet: Figure 6. Effect of FTY720P on lipid accumulation in the presence of (a) the SREBP inhibitor fatostatin. (b) The PPARγ inhibitor GW9662. Values are means ± SEM; N = 5. Bars not sharing a common letter are considered significantly different from each other at P < 0.05.

    Article Snippet: FTY720P (Cat # sc-205332A), rosiglitazone (Cat # sc-202795), anti-SREBP1 (Cat# sc-365513, Lot#B1821), anti-p-mTOR (Cat# sc-293132, Lot#K2717), anti-mTOR (Cat# sc-8319, Lot#K2415), anti-GAPDH (Cat# sc-47724, Lot# H0917) mouse primary antibodies as well as anti-mouse horse radish peroxidase (HRP) conjugated secondary antibodies (Cat# sc-2005, Lot# C2011) were purchased all from Santa Cruz Biotechnology, CA, USA.

    Techniques:

    Figure 13. The signaling pathway activated by FTY720P.

    Journal: Scientific reports

    Article Title: Effect of FTY720P on lipid accumulation in HEPG2 cells.

    doi: 10.1038/s41598-023-46011-4

    Figure Lengend Snippet: Figure 13. The signaling pathway activated by FTY720P.

    Article Snippet: FTY720P (Cat # sc-205332A), rosiglitazone (Cat # sc-202795), anti-SREBP1 (Cat# sc-365513, Lot#B1821), anti-p-mTOR (Cat# sc-293132, Lot#K2717), anti-mTOR (Cat# sc-8319, Lot#K2415), anti-GAPDH (Cat# sc-47724, Lot# H0917) mouse primary antibodies as well as anti-mouse horse radish peroxidase (HRP) conjugated secondary antibodies (Cat# sc-2005, Lot# C2011) were purchased all from Santa Cruz Biotechnology, CA, USA.

    Techniques: